Lupin Receives US FDA Marketing Approval For Generic Welchol Tablets
Pharma major Lupin Limited (Lupin) has received approval for its colesevelam hydrochloride tablets, 625 mg, from the United States Food and Drug Administration (FDA), to market a generic equivalent of Welchol tablets, 625 mg, of Daiichi Sankyo, Inc.Colesevelam hydrochloride tablets, 625 mg, are indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia; to reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH).Colesevelam hydrochloride tablets (RLD: Welchol) had an annual sales of approximately US$ 159 million in the US (IQVIA MAT September 2020)
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
